Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06906809 · ClinicalTrials.gov registry record · Phase 1
Effect of Phenytoin or Itraconazole on How BGB-16673 is Absorbed and Removed From the Body in Healthy Participants
A Phase 1 study, sponsored by BeiGene.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
NCT06906809 is a Phase 1 study that has completed, run by BeiGene. The registered enrollment target is 37 participants.
The verdict
NCT06906809, a Phase 1 study, has completed, sponsored by BeiGene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the effect of coadministration of phenytoin or itraconazole on the pharmacokinetics of BGB-16673 in healthy participants.
Interventions
- DRUG BGB-16673
- DRUG Itraconazole
- DRUG Phenytoin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2025-04-03 |
| Est. Completion | 2025-10-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06906809
The ClinicalTrials.gov registry entry for NCT06906809 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which BGB-16673 is the first listed.
NCT06906809 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06906809 about?
NCT06906809 is a clinical study titled "Effect of Phenytoin or Itraconazole on How BGB-16673 is Absorbed and Removed From the Body in Healthy Participants". The purpose of this study is to investigate the effect of coadministration of phenytoin or itraconazole on the pharmacokinetics of BGB-16673 in healthy participants.
What is the current status of trial NCT06906809?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2025-04-03. Estimated completion is 2025-10-13.
What interventions are being tested in trial NCT06906809?
The interventions under investigation include: BGB-16673 (DRUG), Itraconazole (DRUG), Phenytoin (DRUG).
Who is sponsoring clinical trial NCT06906809?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.